Tablet Coatings - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Tablet coatings market size in 2026 is estimated at USD 1.04 billion, growing from 2025 value of USD 0.986 billion with 2031 projections showing USD 1.33 billion, growing at 5.12% CAGR over 2026-2031. This report is Segmented by Coating Type (Film-Coated, Sugar-Coated, and More, Polymer (Cellulose Ethers, Acrylic Acid Polymers, and More), Formulation Component (Plasticizers, and More), Process/Equipment (Conventional Pan Coating, and More), Application (Immediate-Release, and More), End-User (Pharmaceutical Manufacturers, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD

Global Tablet Coatings Market Trends and Insights

Expeditious Growth Of The Global Pharmaceutical Manufacturing Base

Drug makers have launched an unprecedented wave of bricks-and-mortar expansion. PCI Pharma Services earmarked USD 365 million for coating-friendly lines in the United States and Europe, while CordenPharma allocated EUR 900 million to peptides that rely on sophisticated protective layers. In Asia, WuXi STA activated a 169-acre active-ingredient campus and tripled peptide capacity, reflecting the region’s appetite for complex solid forms. These multimillion-dollar moves immediately lift baseline consumption of coating polymers, pigments, and plasticizers. They also spur downstream investments such as Lotte Fine Chemical’s USD 740 million cellulose pact with Colorcon, which aims to secure a leadership position in excipient supply. As more biologicals make the leap to oral dosage, demand extends beyond conventional barrier films into moisture-tight or enteric layers engineered for fragile APIs. For suppliers, the expanding factory footprint translates into recurring raw-material volumes, steady retrofits of aging pans, and adoption of inline quality controls that favor premium, ready-to-use powders.

Rapid Adoption Of Orphan Drugs & Nutraceuticals

Record orphan-drug approvals and booming nutraceutical launches broaden the coating toolbox. Vertex, Gilead, and peer innovators each spent more than USD 4 billion in 2024 to secure rare-disease candidates that often demand pH-dependent release or micro-layered actives for low-dose accuracy. On the supplement side, Colorcon debuted Nutrapure, the first aqueous clear organic film system, crafted to satisfy clean-label consumers without compromising stability. Evonik’s EUDRAGUARD® line delivers probiotic-friendly enteric functionality, showing how pharmaceutical-grade science migrates into wellness products. Hovione’s pact with Zerion Pharma extends high-surface-area Dispersome carriers to vitamin blends, highlighting the cross-pollination of Rx and OTC technologies. With the FDA now offering clearer notification rules for new dietary ingredients, novel coatings can reach shelves faster while capturing premium margins.

Stringent & Divergent Regional GMP Requirements

Regulatory labyrinths complicate execution. Europe’s 2024 draft medicines law adds layers of supply-chain traceability, while the FDA’s CFR 211.110 revision mandates scientifically justified sampling plans. Asia-Pacific introduces country-specific modules despite PIC/S harmonization, forcing manufacturers to compile overlapping dossiers for India, China, and Japan. For coaters, each jurisdiction can demand fresh validation of inlet air temperature, spray pattern, and cleaning cycles. The added paperwork inflates launch budgets and slows global rollout, blunting some CAGR upside predicted for the tablet coatings market.

Other drivers and restraints analyzed in the detailed report include:

• Growing Demand For Taste-Masking & Aesthetic Coatings For Pediatric And Geriatric Compliance
• Shift Toward Continuous Manufacturing In Solid-Dose Formulations
• Time- and Cost-Intensive Coating Process Validation

Segment Analysis

Film-coated tablets contributed 52.74% of 2025 revenue, underscoring how a single layer can combine moisture protection, UV shielding, and brand color in one economical pass. The tablet coatings market size for enteric-coated formats is projected to rise at 6.73% CAGR as biologic actives and probiotics demand intestine-directed release. Over the next five years, film formulations will integrate digital watermark pigments for anti-counterfeiting and low-foaming surfactants to support continuous lines. Concurrently, sugar-coat demand will stay niche, serving mainly pediatric syrups converted into chewable cores.

Continuous processing magnifies film-coat advantages because the step’s short residence time aligns well with ready-to-use aqueous systems. Hovione’s Lisbon installation links continuous granulation to direct pan coating, demonstrating 30% faster cycle times versus batch. Enteric players innovate with plasticizer-free acrylic dispersions that cut preparation time by 70%, led by Evonik’s EUDRAGIT FL 30 D-55. Suppliers see rising orders for functional films combining delayed and sustained-release layers in single-step processes, saving floor space and validation hours.

Cellulose ethers owned 38.25% of 2025 demand thanks to a decades-long safety record and universal compendial listings. Acrylics, however, show an 7.86% forward CAGR, positioning them as the fastest polymer class in the broader tablet coatings market. Pharmaceutical buyers value acrylics for superior film strength under low solids and for ease of pH tuning, both key for continuous spray. Lotte Fine Chemical’s partnership with Colorcon aims to enlarge cellulose output dramatically, a sign core users still prioritize supply security for traditional grades.

Next-generation acrylics integrate quaternary-amine groups for colon targeting, while bio-based celluloses gain momentum in sustainability audits. The tablet coatings market share that acrylics capture will also benefit from regulatory pressures on TiO2 because many acrylic dispersions mask core discoloration without added opacifiers. Polymer producers invest in green-chemistry solvent recovery and energy-efficient reactors to lower scope-1 emissions, aligning with ESG mandates from top-20 pharma customers.

Complete Report Scope:

• By Coating Type
  • Film-coated
  • Sugar-coated
  • Enteric-coated
  • Functional coatings
  • Other coating types
• By Polymer
  • Cellulose ethers
  • Acrylic acid polymers
  • Vinyl alcohol polymers
  • Polyethylene glycol & derivatives
  • Other polymers
• By Formulation Component
  • Plasticizers
  • Colorants
  • Solvents / Vehicles
  • Opacifiers & anti-tack agents
• By Process / Equipment
  • Conventional pan coating
  • Perforated pan coating
  • Fluidized-bed coating
  • Continuous coating systems
• By Application
  • Immediate-release
  • Sustained-release
  • Extended-release
  • Delayed / enteric release
• By End-User
  • Pharmaceutical manufacturers
  • Nutraceutical & dietary-supplement companies
  • CDMOs & CMOs
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

Asia-Pacific controlled 33.67% of 2025 revenue and is projected for an 7.72% CAGR, making it both the largest and the fastest region in the tablet coatings market. India’s CRDMO operators collectively announce multi-year capex aimed at doubling coated-tablet output by 2030, supported by government production incentives. China’s modernization drive includes WuXi STA’s peptide complex that triples spray-drying and film-coating capacity; Korean player SK pharmteco injects USD 260 million into small-molecule lines, underscoring regional momentum. These investments pull in coating raw materials ranging from hydroxypropyl methylcellulose to specialized color blends.

North America retains its innovation edge. The FDA’s 2025 guideline on continuous processing triggers fresh equipment orders, while USD 160 billion in projected pharmaceutical capex provides a steady pipeline for retrofit opportunities. PCI Pharma’s USD 365 million upgrade and Hovione’s USD 170 million New Jersey expansion highlight the commitment to higher-value coating technologies.

Europe wrestles with regulatory unknowns surrounding TiO2 but compensates through technology leadership and large-scale peptide projects. CordenPharma’s EUR 900 million commitment underlines continued confidence, and Evonik’s restructuring channels resources into high-growth drug-delivery coatings. The upcoming EMA opinion on TiO2 may catalyze a wave of reformulations, providing suppliers of calcium-carbonate opacifiers and polymeric whiteners with new revenue streams.

List of Companies Covered in this Report:

• BPSI Holdings
• BASF
• Evonik Industries
• Ashland Global Holdings
• Kerry Group plc
• Merck
• DuPont
• Sensient Technologies Corp.
• Wincoat Colours & Coatings Pvt Ltd
• Corel Pharma Chem
• JRS Pharma
• Eastman Chemical Company
• Roquette Frères
• Biogrund GmbH
• Ideal Cures Pvt Ltd
• Seppic (Air Liquide)
• Omya AG
• IMCD Group
• DFE Pharma
• ABITEC Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support